FIELD: pharmaceutics.
SUBSTANCE: the present innovation deals with new pharmaceutical compositions based upon medicinal preparation (hydroxymatairesinol) to prevent cancer, hormonallydependent disease or cardio-vascular disease; new methods of prophylaxis including introduction of the above-mentioned compositions, methods to increase blood enterolacton level due to introducing hydroxymatairesinol, food supplement, food product and method to increase resistance of the above-mentioned product. New fields for applying hydroxymatairesinol are efficient due to its anti-tumor, antioxidant activity and body metabolism to enterolacton which, in its turn, is considered to be an inhibitor of aromatase.
EFFECT: increased number of preparation of the mentioned indication.
16 cl, 5 dwg, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR TREATING OESTROGEN-DEPENDENT CANCER | 2012 |
|
RU2510268C1 |
APPLICATION OF FULVESTRANT AT TREATING RESISTANT CANCER OF MAMMARY GLAND | 2001 |
|
RU2265438C2 |
AGENT ELICITING ANTITUMOR EFFECT | 2003 |
|
RU2254139C1 |
SUSTAINED RELEASE SYSTEMS AND LOW DOSES OF ANDROGENS, METHODS OF THEIR PREPARING AND METHOD OF TREATMENT USING THESE SYSTEMS | 1992 |
|
RU2142276C1 |
METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN EITHER DURING OR AFTER MENOPAUSE | 2001 |
|
RU2268035C2 |
METHOD OF TREATING CYSTIC FIBROSIS OF BREAST IN FEMALES OF REPRODUCTIVE AGE | 2011 |
|
RU2456009C1 |
METHODS OF PREVENTION OR TREATMENT OF SARCOPENIA OR MUSCLE ATROPHY IN ANIMALS | 2010 |
|
RU2558534C2 |
DIETARY SUPPLEMENT | 2008 |
|
RU2376887C1 |
METHOD FOR CORRECTION OF HYPERESTRADIOLEMIA AND NORMOGONADOTROPIC HYPOGONADISM IN MALES | 2010 |
|
RU2474424C2 |
METHOD FOR ESTIMATING TUMOR HORMONE DEPENDENCE OF LOW-DIFFERENTIATED ENDOMETRIUM CARCINOMA AND ITS SENSITIVITY TO AROMATASE INHIBITORS | 2006 |
|
RU2317555C2 |
Authors
Dates
2004-12-10—Published
2000-03-09—Filed